TACSTD2 and neoplasm: This study analyzes the heterogeneity of TROP2 expression levels within the primary tumor and the heterogeneity of expression levels in systemic metastases, thereby providing a base for testing whether the patient is suitable for subsequent treatment and conducive to the formulation of subsequent treatment plans.